| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 04/03/2024 | 18:22 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 28/02/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 26/02/2024 | 23:28 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 26/02/2024 | 23:28 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 22/02/2024 | 14:50 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 22/02/2024 | 14:45 | GlobeNewswire Inc. | Gracell Biotechnologies Acquisition Completed | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 20/02/2024 | 13:45 | GlobeNewswire Inc. | Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 14/02/2024 | 14:20 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 29/01/2024 | 13:00 | GlobeNewswire Inc. | Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 08/01/2024 | 16:06 | PR Newswire (US) | Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law Firm | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 26/12/2023 | 12:44 | Dow Jones News | Gracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZeneca | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 26/12/2023 | 09:05 | Dow Jones News | AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 26/12/2023 | 08:01 | Business Wire | AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 26/12/2023 | 08:00 | GlobeNewswire Inc. | Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 21/12/2023 | 13:00 | GlobeNewswire Inc. | Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/12/2023 | 01:30 | GlobeNewswire Inc. | Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 29/11/2023 | 12:18 | IH Market News | Amazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and More | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 28/11/2023 | 20:59 | Dow Jones News | Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 27/11/2023 | 14:00 | GlobeNewswire Inc. | Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 21/11/2023 | 12:25 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 16/11/2023 | 14:00 | GlobeNewswire Inc. | Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 13/11/2023 | 13:30 | GlobeNewswire Inc. | Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 08/11/2023 | 14:30 | GlobeNewswire Inc. | Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/11/2023 | 14:00 | GlobeNewswire Inc. | Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 01/11/2023 | 21:00 | GlobeNewswire Inc. | Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 31/10/2023 | 14:00 | GlobeNewswire Inc. | Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 30/10/2023 | 13:30 | GlobeNewswire Inc. | Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023 | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 27/09/2023 | 14:30 | GlobeNewswire Inc. | Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 26/09/2023 | 22:00 | GlobeNewswire Inc. | Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 19/09/2023 | 15:21 | GlobeNewswire Inc. | Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders | NASDAQ:GRCL | Gracell Biotechnologies Inc |
